Heidelberg Pharma AG reported earnings results for the second quarter and six months ended May 31, 2023. For the second quarter, the company reported sales was EUR 2.32 million compared to EUR 11.22 million a year ago. Net loss was EUR 9.39 million compared to EUR 1.36 million a year ago. Basic loss per share from continuing operations was EUR 0.2 compared to EUR 0.04 a year ago.
For the six months, sales was EUR 4.39 million compared to EUR 11.93 million a year ago. Revenue was EUR 4.67 million compared to EUR 12.17 million a year ago. Net loss was EUR 15.95 million compared to EUR 8.6 million a year ago. Basic loss per share from continuing operations was EUR 0.34.